Drugs

On April 24, 2025, a U.S. judge rejected a bid by compounding pharmacies to continue producing copies of Novo Nordisk’s Ozempic and Wegovy, drugs critical for diabetes and weight loss. This ruling, centered on the active ingredient semaglutide, highlights tensions over drug shortages, compounding practices, and access to essential medications. Here’s a concise look at the decision, its implications, and the background.

In 2025, weight loss drugs have taken center stage in global health discussions — and Orforglipron, a new oral GLP-1 receptor agonist, is creating buzz. With its pill-based format (unlike injectables like Ozempic or Wegovy), it’s seen as a potential game-changer. But how much does it cost? Is it really affordable? And what do current … Read more

In a remarkable development within the field of obesity medicine, researchers are exploring less invasive alternatives to injectable weight-loss drugs, including topical creams and patches, also known as transdermal drug delivery systems. These innovations are aimed at delivering obesity medication without the use of needles—addressing a key barrier for millions of individuals who are needle-averse. … Read more

Retatrutide, an investigational drug developed by Eli Lilly, is making waves in the field of obesity treatment. Currently in clinical trials, this promising medication has shown remarkable potential to drive significant weight loss and improve metabolic health, positioning it as a possible game-changer in the fight against obesity. Here’s an in-depth look at what makes … Read more